Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2011

View Archived Issues

Interim first-in-human data released on two c-Met inhibitors

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Halozyme discloses clinical results on new Herceptin formulation

Pulmonary Fibrosis Foundation to fund independent evaluation of Compugen's candidate for IPF

Orantinib advances through studies in NSCLC and breast cancer

U.S. universities assess CDME in model of cystinuria

Analyses focus on cardiovascular risk with naltrexone/bupropion

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Phase I study of PPI-668 commences

CSIR presents new antitumor agents

Takeda commences international phase III program for TAK-875

Lpath begins dosing in second proof-of-concept iSONEP trial

Studies confirm efficacy of Transcend-trastuzumab conjugate in HER2-positive breast cancer

Encore Therapeutics completes proof-of-concept study of ETI-511

Novel vitamin D receptor ligands synthesized at WARF

FDA clears IsoAmp HSV assay

Nile Therapeutics completes dosing in subcutaneous cenderitide trial

Phase I MultiStem study advances

Actelion Pharmaceuticals reports new prostanoid DP2 receptor antagonists

FDA approves MethylGene's IND for new study of antifungal product candidate

Lux Biosciences withdraws Luveniq MAA

Almirall and Lundbeck enter agreement to copromote escitalopram

EMA delays review of Flutiform MAA

Isotechnika receives scientific advice from EMA for voclosporin trial

Malaria vaccine RTS,S/ASO1E shows efficacy in African children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...